We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

17 hedge funds and large institutions have $1.28M invested in Processa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

6% less funds holding

Funds holding: 18 → 17 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

51% less capital invested

Capital invested by funds: $2.58M → $1.28M (-$1.31M)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RJFSA
Raymond James Financial Services Advisors
Florida
+$94.7K
2
MCP
Mirador Capital Partners
California
+$41.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.73K
4
TRCT
Tower Research Capital (TRC)
New York
+$6.76K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.83K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$111K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$28K
3
EIM
Essex Investment Management
Massachusetts
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$411K +$966 +1 +0.1%
ACM
2
AIGH Capital Management
Maryland
$334K – – –
WVP
3
Worth Venture Partners
New Jersey
$78K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$75K +$7.73K +8 +6%
VCA
5
Verdence Capital Advisors
Maryland
$65.9K – – –
CBA
6
Coastal Bridge Advisors
Connecticut
$57.8K – – –
RJFSA
7
Raymond James Financial Services Advisors
Florida
$53.8K +$94.7K +98 New
Janney Montgomery Scott
8
Janney Montgomery Scott
Pennsylvania
$51K – – –
State Street
9
State Street
Massachusetts
$47.1K – – –
BlackRock
10
BlackRock
New York
$31.3K +$966 +1 +2%
MCP
11
Mirador Capital Partners
California
$23.4K +$41.5K +43 New
Northern Trust
12
Northern Trust
Illinois
$16.9K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$16K +$4.83K +5 +22%
TRCT
14
Tower Research Capital (TRC)
New York
$9K +$6.76K +7 +78%
Wells Fargo
15
Wells Fargo
California
$3.47K – – –
AF
16
Allworth Financial
California
$1.87K – – –
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$1K – – –
Bank of America
18
Bank of America
North Carolina
$15 – – –
Morgan Stanley
19
Morgan Stanley
New York
– -$111K -98 Closed
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
– -$28K -25 Closed
EIM
21
Essex Investment Management
Massachusetts
– -$5K -5 Closed

PCSA Hedge Fund Activity: Q4 2022 in Review

17 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2022, worth a combined $1.28M — down 51% from $2.58M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of PCSA and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 5 added.

The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $94.7K. The largest seller was Morgan Stanley, exiting entirely with an estimated $111K sold.

  • 17 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2022, down from 18 in Q3 2022.
  • Funds reported $1.28M of Processa Pharmaceuticals stock for Q4 2022, down 51% quarter-over-quarter.
  • 2 funds opened new Processa Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of -1 holder.
  • The largest Processa Pharmaceuticals buyer in Q4 2022 was Raymond James Financial Services Advisors, an estimated $94.7K added.
  • The largest Processa Pharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $111K sold.

Based on aggregated 13F filings for Q4 2022.